Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer

被引:1
|
作者
Peters, Gabrielle W. [1 ]
Talcott, Wesley [1 ]
Peters, Nicholas V. [2 ]
Dhanasopan, Andrew [3 ]
Lacy, Jill [4 ]
Cecchini, Michael [4 ]
Kortmansky, Jeremy [4 ]
Stein, Stacey [4 ]
Lattanzi, Stephen [4 ]
Park, Henry S. [1 ]
Boffa, Daniel [3 ]
Johung, Kimberly L. [1 ]
Jethwa, Krishan R. [5 ]
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT USA
[2] Yale Univ, Dept Gen Surg, Sch Med, New Haven, CT USA
[3] Yale Univ, Dept Thorac Surg, Sch Med, New Haven, CT USA
[4] Yale Univ, Dept Med Oncol, Sch Med, New Haven, CT USA
[5] Mayo Clin, Radiat Oncol, Rochester, MN USA
关键词
Induction chemotherapy; esophageal cancer; gastroesophageal cancer; PHASE-II TRIAL; NEOADJUVANT CHEMORADIOTHERAPY; TREATMENT TIME; PLUS SURGERY; THERAPY; SURVIVAL; IMPACT;
D O I
10.21037/jgo-22-1005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: For patients with operable locally advanced esophageal carcinoma (LA-EC), we hypothesized that pre-operative induction chemotherapy followed by chemoradiotherapy (IC-CRT) would improve progression-free survival (PFS) and overall survival (OS) when compared to chemoradiotherapy (CRT). Methods: This was a single institution retrospective cohort study including patients with LA-EC who received preoperative-intent IC-CRT vs. CRT between 2013-2019. The Kaplan-Meier method was used to estimate OS and PFS. Cox proportional hazards regression was used to assess for variables associated with survival. The impact of treatment group on pathologic response was assessed by chi-square. Results: Ninty-five patients were included for analysis (IC-CRT n=59; CRT n=36) and the median followup was 37.7 months (IQR: 16.8-56.1). There was no difference in median PFS or OS for IC-CRT or CRT, 22 months (95% CI: 12-59) vs. 32 months (95% CI: 10-57) (P=0.64) and 39 months ( 95% CI: 23-not reached) vs. 56.5 months (95% CI: 38-not reached) (P=0.36), respectively. Amongst the subset of patients with adenocarcinoma histology, there was no difference in median PFS or OS, nor was there when analyses were further restricted to those who received >= 3 cycles of induction 5-fluorouracil and platinum, or for those who underwent esophagectomy. Pathologic complete response occurred in 45% vs. 29% (P=0.24) and N-stage regression occurred in 72% vs. 58% (P= 0.28) of patients in the IC- CRT and CRT cohorts, respectively. Distant metastasis occurred in 44% of patients in each treatment cohort. Conclusions: For patients with LA-EC, preoperative-intent IC-CRT was not associated with improved PFS or OS when compared with CRT.
引用
收藏
页码:1181 / +
页数:16
相关论文
共 50 条
  • [31] Role of vindesine in induction chemotherapy in locally-advanced non-small-cell lung cancer
    Jürgen R. Fischer
    Peter Drings
    Journal of Cancer Research and Clinical Oncology, 1998, 124 : 4 - 9
  • [32] Role of vindesine in induction chemotherapy in locally-advanced non-small-cell lung cancer
    Fischer, JR
    Drings, P
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1998, 124 (01) : 4 - 9
  • [33] Restaging after chemoradiotherapy for locally advanced esophageal cancer
    Defize, Ingmar L.
    van Hillegersberg, Richard
    Mook, Stella
    Meijer, Gert J.
    Lin, Steven H.
    Ruurda, Jelle P.
    van Rossum, Peter S. N.
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [34] Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers
    Maemura, Kosei
    Mataki, Yuko
    Kurahara, Hiroshi
    Kawasaki, Yota
    Iino, Satoshi
    Sakoda, Masahiko
    Uchikado, Yasuto
    Arigami, Takaaki
    Uenosono, Yoshikazu
    Mori, Shinichiro
    Ueno, Shinichi
    Shinchi, Hiroyuki
    Natsugoe, Shoji
    ANTICANCER RESEARCH, 2017, 37 (01) : 233 - 237
  • [35] Phase II study of preoperative concurrent chemoradiotherapy with oxaliplatin for locally advanced esophageal cancer
    Huang, Jing-Wen
    Yeh, Hui-Ling
    Hsu, Chung-Ping
    Chuang, Cheng-Yen
    Lin, Jin-Ching
    Lin, Jai-Fu
    Chang, Chen-Fa
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2017, 80 (07) : 401 - 407
  • [36] Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer
    Wongwaiyut, Kraipop
    Ruangsin, Sakchai
    Laohawiriyakamol, Supparerk
    Leelakiatpaiboon, Siriporn
    Sangthawan, Duangjai
    Sunpaweravong, Patrapim
    Sunpaweravong, Somkiat
    JOURNAL OF GASTROINTESTINAL CANCER, 2020, 51 (03) : 947 - 951
  • [37] Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study
    Elliott, Jessie A.
    Klevebro, Fredrik
    Mantziari, Styliani
    Markar, Sheraz R.
    Goense, Lucas
    Johar, Asif
    Lagergren, Pernilla
    Zaninotto, Giovanni
    van Hillegersberg, Richard
    Henegouwen, Mark I. van Berge
    Schafer, Markus
    Nilsson, Magnus
    Hanna, George B.
    Reynolds, John V.
    ANNALS OF SURGERY, 2023, 278 (05) : 692 - 700
  • [38] Surgery After Induction Chemotherapy or Chemoradiotherapy for Locally Advanced Lung Cancer A Technical Challenge
    Asamura, Hisao
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1458 - 1459
  • [39] Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
    Zhang, Baihua
    Zhao, Hongbo
    Wu, Xun
    Gong, Lianghui
    Yang, Desong
    Li, Xu
    Chen, Xiaoyan
    Li, Jigang
    Wang, Wenxiang
    Wu, Jie
    Xiao, Qin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [40] Induction Chemotherapy Followed by Chemoradiotherapy With or Without Consolidation Chemotherapy Versus Chemoradiotherapy Followed by Consolidation Chemotherapy for Esophageal Squamous Cell Carcinoma
    Xiang, Mingyue
    Liu, Bo
    Zhang, Guifang
    Gong, Heyi
    Han, Dali
    Ma, Changsheng
    FRONTIERS IN ONCOLOGY, 2022, 12